AAIC 2026: Genetic Biomarkers and Precision Medicine

Overview

Overview

The integration of genetic biomarkers with PET imaging, fluid biomarkers, and clinical data represents the frontier of precision medicine in [Alzheimer's disease](/diseases/alzheimers-disease) (AD). At AAIC 2026, researchers presented significant advances in using genetic information—including [APOE](/proteins/apoe) genotype, polygenic risk scores (PRS), and rare variant genotyping—to guide biomarker interpretation, predict disease progression, and personalize therapeutic approaches["@stGeorge2019"].

Why Genetic Biomarkers Matter for Precision Medicine

Genetic information provides several unique advantages for AD precision medicine:

Conference Coverage

1. APOE Genotype Integration with Biomarkers

APOE genotype strongly influences biomarker profiles:

| APOE Status | Amyloid PET | CSF Aβ42/40 | CSF p-tau181 | Clinical Response |
|-------------|-------------|-------------|--------------|-------------------|
| ε4/ε4 | Highest positivity | Lowest levels | Highest levels | More rapid decline |
| ε3/ε4 | Intermediate | Intermediate | Intermediate | Typical progression |
| ε3/ε3 | Lowest | Highest | Lowest | Slowest progression |

Key AAIC 2026 findings:

• APOE ε4 carriers show distinct [tau](/proteins/tau) PET patterns despite similar amyloid burden
• Blood [p-tau217](/biomarkers/p-tau-217) performance varies by APOE genotype
• APOE dosage affects [GFAP](/entities/gfap) as astrogliosis marker

2. Polygenic Risk Scores (PRS)

PRS integrate information from multiple genetic risk loci:

• AD PRS combines ~30-100 risk variants
• Brain volume PRS predicts hippocampal atrophy
• Cognitive PRS correlates with executive function decline

• PRS can identify high-risk individuals before amyloid positivity
• PRS stratifies participants for clinical trials
• PRS combined with biomarkers improves progression prediction

3. Rare Genetic Variants

Rare variants in multiple genes influence AD risk:

| Gene | Variant | Effect | Biomarker Implication |
|------|---------|--------|----------------------|
| [TREM2](/proteins/trem2-protein) | R47H, R62H | 3x risk increase | Altered microglial response |
| [SORL1](/proteins/sorl1) | LoF variants | 2-3x risk | Reduced amyloid clearance |
| [ABCA7](/proteins/abca7-protein) | LoF variants | 1.5-2x risk | Phagocytosis deficits |
| [PLD3](/proteins/pld3) | LoF variants | 2x risk | Lysosomal function |

AAIC 2026 highlights:

• TREM2 variant carriers show enhanced response to anti-amyloid therapies
• SORL1 deficiency correlates with specific CSF biomarker patterns

4. Integration with PET Imaging

Genetic information enhances PET interpretation:

• Amyloid PET — APOE ε4 carriers may show earlier neocortical binding
• Tau PET — Genetic risk influences regional tau patterns
• FDG-PET — APOE affects default mode network connectivity
• PET guidance — PRS identifies optimal PET timing for screening

5. Integration with Fluid Biomarkers

Genetic-fluid biomarker integration:

• CSF biomarkers — APOE affects Aβ42/40 ratio interpretation
• Blood biomarkers — p-tau217 performance varies by genotype
• Neurofilament light chain (NfL) — Genetic variants predict baseline levels

Precision Medicine Applications

1. Clinical Trial Enrichment

Genetic stratification improves trial design:

| Strategy | Genetic Approach | Benefit |
|----------|------------------|---------|
| Enrichment | APOE ε4 selection | Higher event rate |
| Stratification | PRS tiering | Homogeneous subgroups |
| Exclusion | Risk variant removal | Reduced confounding |
| Endpoint | Genetic progression modifiers | Adjusted expectations |

2. Therapeutic Selection

Genotype-guided treatment decisions:

• Anti-amyloid antibodies — APOE ε4 carriers may need lower doses
• TREM2 agonists — May work better in TREM2 variant carriers
• Anti-tau therapies — May be more effective in specific genotypes

3. Prevention Strategies

Genetic-informed prevention:

• APOE ε4 carriers — Earlier biomarker screening recommended
• High PRS individuals — Aggressive lifestyle intervention
• Rare variant carriers — Consider clinical trial participation

Cross-Linking to NeuroWiki

Genetic Biomarker Pages

• [APOE Protein](/proteins/apoe-protein) — Major AD risk gene](/proteins)
• [TREM2 Protein](/proteins/trem2-protein) — Microglial risk gene](/proteins)
• [SORL1 Protein](/proteins/sorl1) — Trafficking protein](/proteins)
• [ABCA7 Protein](/proteins/abca7-protein) — Lipid transporter

Biomarker Integration

• [AAIC 2026: Multi-Modal Biomarker Integration](/events/aaic-2026/biomarker-integration)](/events)
• [AAIC 2026: PET + Fluid Combination](/events/aaic-2026/biomarker-integration/pet-fluid-combination)](/events)
• [AAIC 2026: Blood Biomarker Validation](/events/aaic-2026/biomarker-integration/blood-biomarkers-validation)

Precision Medicine

• [Precision Medicine for Neurodegeneration](/therapeutics/precision-medicine-neurodegeneration)](/therapeutics)
• [APOE Genotype-Guided Prevention](/therapeutics/apoe-genotype-guided-prevention)

AAIC 2026 Related

• [AAIC 2026: Gene Therapy Developments](/events/aaic-2026/gene-therapy-developments)](/events)
• [AAIC 2026: Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)](/events)
• [AAIC 2026: Clinical Trials](/events/aaic-2026/clinical-trials-update)

Future Directions

Key areas for future research highlighted at AAIC 2026:

References